Mucosal Immunization with Live Attenuated Francisella Novicida U112ΔiglB Protects Against Pulmonary F. Tularensis SCHU S4 in the Fischer 344 Rat Model

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2012 Nov 3

PMID 23118885

Citations 18

Authors

Aimee L Signarovitz

Heather J Ray

Jieh-Juen Yu

M N Guentzel

James P Chambers

Karl E Klose

Bernard P Arulanandam

Affiliations

Soon will be listed here.

Abstract

The need for an efficacious vaccine against Francisella tularensis is a consequence of its low infectious dose and high mortality rate if left untreated. This study sought to characterize a live attenuated subspecies novicida-based vaccine strain (U112ΔiglB) in an established second rodent model of pulmonary tularemia, namely the Fischer 344 rat using two distinct routes of vaccination (intratracheal [i.t.] and oral). Attenuation was verified by comparing replication of U112ΔiglB with wild type parental strain U112 in F344 primary alveolar macrophages. U112ΔiglB exhibited an LD(50)>10(7) CFU compared to the wild type (LD(50) = 5 × 10(6) CFU i.t.). Immunization with 10(7) CFU U112ΔiglB by i.t. and oral routes induced antigen-specific IFN-γ and potent humoral responses both systemically (IgG2a>IgG1 in serum) and at the site of mucosal vaccination (respiratory/intestinal compartment). Importantly, vaccination with U112ΔiglB by either i.t. or oral routes provided equivalent levels of protection (50% survival) in F344 rats against a subsequent pulmonary challenge with ~25 LD(50) (1.25 × 10(4) CFU) of the highly human virulent strain SCHU S4. Collectively, these results provide further evidence on the utility of a mucosal vaccination platform with a defined subsp. novicida U112ΔiglB vaccine strain in conferring protective immunity against pulmonary tularemia.

Citing Articles

Marmosets as models of infectious diseases.

Herron I, Laws T, Nelson M Front Cell Infect Microbiol. 2024; 14:1340017.

PMID: 38465237 PMC: 10921895. DOI: 10.3389/fcimb.2024.1340017.

Secretory System Components as Potential Prophylactic Targets for Bacterial Pathogens.

Swietnicki W Biomolecules. 2021; 11(6).

PMID: 34203937 PMC: 8232601. DOI: 10.3390/biom11060892.

Protective effects of the Francisella tularensis ΔpdpC mutant against its virulent parental strain SCHU P9 in Cynomolgus macaques.

Tian D, Uda A, Ami Y, Hotta A, Park E, Nagata N Sci Rep. 2019; 9(1):9193.

PMID: 31235714 PMC: 6591246. DOI: 10.1038/s41598-019-45412-8.

An O-Antigen Glycoconjugate Vaccine Produced Using Protein Glycan Coupling Technology Is Protective in an Inhalational Rat Model of Tularemia.

Marshall L, Nelson M, Davies C, Whelan A, Jenner D, Moule M J Immunol Res. 2019; 2018:8087916.

PMID: 30622981 PMC: 6304830. DOI: 10.1155/2018/8087916.

Lipoxin A4 receptor agonist BML-111 induces autophagy in alveolar macrophages and protects from acute lung injury by activating MAPK signaling.

Liu H, Zhou K, Liao L, Zhang T, Yang M, Sun C Respir Res. 2018; 19(1):243.

PMID: 30518355 PMC: 6282312. DOI: 10.1186/s12931-018-0937-2.

References

Kadzhaev K, Zingmark C, Golovliov I, Bolanowski M, Shen H, Conlan W . Identification of genes contributing to the virulence of Francisella tularensis SCHU S4 in a mouse intradermal infection model. PLoS One. 2009; 4(5):e5463. PMC: 2675058. DOI: 10.1371/journal.pone.0005463. View

Kim T, Pinkham J, Heninger S, Chalabaev S, Kasper D . Genetic modification of the O-polysaccharide of Francisella tularensis results in an avirulent live attenuated vaccine. J Infect Dis. 2011; 205(7):1056-65. PMC: 3295600. DOI: 10.1093/infdis/jir620. View

Tanaka N, Fukuyama S, Fukuiwa T, Kawabata M, Sagara Y, Ito H . Intranasal immunization with phosphorylcholine induces antigen specific mucosal and systemic immune responses in mice. Vaccine. 2007; 25(14):2680-7. DOI: 10.1016/j.vaccine.2006.10.014. View

Conlan J, Shen H, Golovliov I, Zingmark C, Oyston P, Chen W . Differential ability of novel attenuated targeted deletion mutants of Francisella tularensis subspecies tularensis strain SCHU S4 to protect mice against aerosol challenge with virulent bacteria: effects of host background and route of immunization. Vaccine. 2009; 28(7):1824-31. PMC: 2822029. DOI: 10.1016/j.vaccine.2009.12.001. View

DOWNS C, CORIELL L . Studies on tularemia; the comparative susceptibility of various laboratory animals. J Immunol Virus Res Exp Chemother. 2010; 56(3):217-28. View

Wu T, Hutt J, Garrison K, Berliba L, Zhou Y, Lyons C . Intranasal vaccination induces protective immunity against intranasal infection with virulent Francisella tularensis biovar A. Infect Immun. 2005; 73(5):2644-54. PMC: 1087315. DOI: 10.1128/IAI.73.5.2644-2654.2005. View

Elkins K, Bosio C . Importance of B cells, but not specific antibodies, in primary and secondary protective immunity to the intracellular bacterium Francisella tularensis live vaccine strain. Infect Immun. 1999; 67(11):6002-7. PMC: 96986. DOI: 10.1128/IAI.67.11.6002-6007.1999. View

Santic M, Molmeret M, Barker J, Klose K, Dekanic A, Doric M . A Francisella tularensis pathogenicity island protein essential for bacterial proliferation within the host cell cytosol. Cell Microbiol. 2007; 9(10):2391-403. DOI: 10.1111/j.1462-5822.2007.00968.x. View

Liu J, Zogaj X, Barker J, Klose K . Construction of targeted insertion mutations in Francisella tularensis subsp. novicida. Biotechniques. 2007; 43(4):487-90, 492. DOI: 10.2144/000112574. View

10.

Hara H, Monsonego A, Yuasa K, Adachi K, Xiao X, Takeda S . Development of a safe oral Abeta vaccine using recombinant adeno-associated virus vector for Alzheimer's disease. J Alzheimers Dis. 2004; 6(5):483-8. DOI: 10.3233/jad-2004-6504. View

11.

Duckett N, Olmos S, Durrant D, Metzger D . Intranasal interleukin-12 treatment for protection against respiratory infection with the Francisella tularensis live vaccine strain. Infect Immun. 2005; 73(4):2306-11. PMC: 1087453. DOI: 10.1128/IAI.73.4.2306-2311.2005. View

12.

Mougous J, Cuff M, Raunser S, Shen A, Zhou M, Gifford C . A virulence locus of Pseudomonas aeruginosa encodes a protein secretion apparatus. Science. 2006; 312(5779):1526-30. PMC: 2800167. DOI: 10.1126/science.1128393. View

13.

Sabirov A, Metzger D . Intranasal vaccination of infant mice induces protective immunity in the absence of nasal-associated lymphoid tissue. Vaccine. 2008; 26(12):1566-76. PMC: 2323833. DOI: 10.1016/j.vaccine.2008.01.027. View

14.

Elkins K, Cowley S, Bosio C . Innate and adaptive immune responses to an intracellular bacterium, Francisella tularensis live vaccine strain. Microbes Infect. 2003; 5(2):135-42. DOI: 10.1016/s1286-4579(02)00084-9. View

15.

Schmerk C, Duplantis B, Wang D, Burke R, Chou A, Elkins K . Characterization of the pathogenicity island protein PdpA and its role in the virulence of Francisella novicida. Microbiology (Reading). 2009; 155(Pt 5):1489-1497. PMC: 2889412. DOI: 10.1099/mic.0.025379-0. View

16.

OLSUFIEV N, EMELYANOVA O, DUNAYEVA T . Comparative study of strains of B. tularense in the old and new world and their taxonomy. J Hyg Epidemiol Microbiol Immunol. 1959; 3:138-49. View

17.

Neutra M, Mantis N, Kraehenbuhl J . Collaboration of epithelial cells with organized mucosal lymphoid tissues. Nat Immunol. 2001; 2(11):1004-9. DOI: 10.1038/ni1101-1004. View

18.

Kweon M . Sublingual mucosa: A new vaccination route for systemic and mucosal immunity. Cytokine. 2011; 54(1):1-5. DOI: 10.1016/j.cyto.2010.12.014. View

19.

Kiyono H, Fukuyama S . NALT- versus Peyer's-patch-mediated mucosal immunity. Nat Rev Immunol. 2004; 4(9):699-710. PMC: 7097243. DOI: 10.1038/nri1439. View

20.

Powell H, Cong Y, Yu J, Guentzel M, Berton M, Klose K . CD4+ T cells are required during priming but not the effector phase of antibody-mediated IFN-gamma-dependent protective immunity against pulmonary Francisella novicida infection. Immunol Cell Biol. 2008; 86(6):515-22. DOI: 10.1038/icb.2008.31. View